IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Phytoconstituent-Based Neuroprotection in Alzheimer's Disease: Mechanisms, Computational Screening, Admet, Quality by Design and Preclinical Translation

Sohel S. Shaikh[1], Dr. Ravi U. Kurhade[2], Dr. Amol R. Kshirsagar[3], Baliram A. Lawate[4], Nishinandan M. Shinde[5]

[1]M. Pharm Final Year Student, Department of Pharmacology
[2]Principal, Department of Pharmaceutics
[3]Professor, Department of Pharmacology
[4]Assistant Professor, Department of Pharmachemistry
[5]Assistant Professor, Department of Pharmaceutics
MDA School of Pharmacy, Kolpa, Latur, Maharashtra

Abstract: *Alzheimer's disease is a progressive neurodegenerative disorder characterized by overlapping amyloid, tau, synaptic, cholinergic, oxidative, inflammatory and mitochondrial mechanisms. Interest in phytoconstituents has increased because flavonoids, polyphenols, catechins, alkaloids and related natural molecules may interact with multiple biological pathways relevant to neuronal stress. This review summarizes the mechanistic rationale for phytoconstituent-based neuroprotection, focusing on antioxidant activity, anti-inflammatory regulation, cholinesterase modulation, amyloid-related mechanisms, mitochondrial protection and behavioural-model interpretation. The review also discusses the role of molecular docking, ADMET prediction and Quality by Design in improving preclinical decision-making. Although several phytoconstituents show promising screening profiles, translation remains limited by solubility, bioavailability, metabolism, blood-brain barrier exposure, model validity and reproducibility concerns. Therefore, phytoconstituents should be interpreted as candidates requiring rigorous validation rather than as established therapies. A structured research pathway linking literature rationale, target-based screening, ADMET filters, ethical animal models, biochemical endpoints, histopathology and statistical transparency can improve the quality of future neuroprotective investigations.*

Keywords: Alzheimer's disease; phytoconstituents; flavonoids; polyphenols; neuroinflammation; oxidative stress; ADMET; QbD

I. INTRODUCTION

Alzheimer's disease is a major neurodegenerative condition associated with gradual decline in memory and daily functional independence. It cannot be fully explained by one mechanism, because amyloid-related toxicity, tau pathology, synaptic dysfunction, cholinergic deficit, oxidative stress, mitochondrial impairment and neuroinflammation operate together over time [1-12].

Phytoconstituents are relevant to this field because many natural molecules show multi-target chemical behaviour. Flavonoids and polyphenols can donate electrons, interact with enzymes, modulate inflammatory pathways and influence oxidative stress. Nevertheless, a plant-derived molecule should not be considered effective only because it has natural

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

origin. Scientific relevance depends on reproducible evidence, reliable chemical identity, dose feasibility, pharmacokinetic suitability and biological validation.

This review organizes the evidence into mechanistic, computational and preclinical themes. It also explains how Quality by Design can be used as a planning tool to improve reproducibility and transparency in phytoconstituent-based neuroprotection studies.



Figure 1. Mechanistic network supporting multi-target phytoconstituent evaluation.

II. MECHANISTIC BACKGROUND OF ALZHEIMER'S DISEASE

Alzheimer's disease is commonly associated with extracellular amyloid-beta aggregation and intracellular tau-related pathology, but these processes interact with metabolic stress, vascular changes, synaptic failure, neuroinflammatory activation and neurotransmitter imbalance. This explains why a compound with only one favourable property may not produce meaningful biological improvement. For preclinical research, the most defensible design is one that connects disease mechanism with measurable endpoints.

Table 1. Major Alzheimer's disease mechanisms and endpoint relevance.

Mechanism	Disease relevance	Useful preclinical endpoint
Amyloid-related injury	Protein aggregation and synaptic disturbance	BACE1/amyloid-related target screening; histology support
Tau pathology	Axonal transport and neuronal integrity impairment	Tissue architecture and neuronal damage scoring
Cholinergic dysfunction	Memory impairment and acetylcholine breakdown	AChE activity and behavioural memory tests
Oxidative stress	Lipid peroxidation and antioxidant depletion	MDA, SOD, catalase and GSH
Neuroinflammation	Microglial activation and cytokine-related neuronal injury	Inflammatory marker panel and histological interpretation
Mitochondrial stress	Energy failure and reactive oxygen species generation	Oxidative stress markers and functional behaviour

DOI: 10.48175/IJARSCT-37822

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

III. PHYTOCONSTITUENTS AS MULTI-TARGET CANDIDATES

The major phytoconstituent groups discussed in Alzheimer's disease research include flavonols, flavones, stilbenes, phenolic acids, catechins, diarylheptanoids and alkaloids. Their mechanistic appeal is related to antioxidant potential, inflammatory modulation, enzyme interaction and possible effects on amyloid or tau-associated pathways [44-62].

Table 2. Selected phytoconstituents and their neuroprotective rationale.

Phytoconstituent	Chemical group	Main rationale	Key limitation
Quercetin	Flavonol	Antioxidant, anti-inflammatory and cholinesterase-related potential	High polarity and bioavailability concerns
Curcumin	Diarylheptanoid polyphenol	Anti-inflammatory and anti-amyloid rationale	Poor solubility and rapid metabolism
Resveratrol	Stilbene polyphenol	Sirtuin-related and antioxidant mechanisms	Metabolic instability and exposure variability
Berberine	Isoquinoline alkaloid	Cholinesterase, inflammatory and metabolic relevance	Dose-related safety and transporter concerns
Luteolin	Flavone	Inflammation modulation and antioxidant support	Limited central exposure may require verification
Apigenin	Flavone	Neuroprotective and anti-inflammatory reports	Dose and bioavailability require confirmation
Rosmarinic acid	Phenolic acid ester	Oxidative injury and cholinesterase-linked support	High polarity may limit CNS penetration
EGCG	Catechin	Multi-target antioxidant and neuronal protection reports	Stability and BBB concerns

IV. ROLE OF MOLECULAR DOCKING AND ADMET SCREENING

Molecular docking supports early hypothesis generation by predicting whether a ligand can occupy a target pocket and form plausible interactions with relevant residues. For Alzheimer's disease, common targets include acetylcholinesterase, butyrylcholinesterase, BACE1 and other guide-approved proteins. Docking should not be interpreted as proof of efficacy; it is a prioritization tool that requires experimental confirmation [66-80].

ADMET prediction is important because a neuroprotective candidate must reach or influence the central nervous system without unacceptable toxicity. Physicochemical parameters such as molecular weight, LogP and topological polar surface area help describe drug-likeness, while predicted absorption, BBB permeability, CYP interaction and toxicity alerts help identify candidates that require formulation support or further safety screening.

Table 3. Computational methods and interpretation limits.

Tool / method	Information generated	Main value	Limitation
PubChem / chemical database	Structure, formula and identifiers	Prevents identity mismatch	Does not prove biological activity
Protein Data Bank	Protein structure and ligand environment	Supports target preparation	Resolution and missing residues must be checked
AutoDock Vina / docking tools	Binding energy and pose	Prioritizes possible target interaction	Score alone cannot prove efficacy
SwissADME / pkCSM / admetSAR	Physicochemical and ADMET profile	Screens CNS suitability and safety flags	Predictions require laboratory confirmation
Visualization software	Ligand-residue interaction image	Improves residue-level interpretation	Unclear images may mislead if not labelled

DOI: 10.48175/IJARSCT-37822

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2



Figure 2. Proposed screening-to-validation pathway for phytoconstituent review and study planning.

V. PRECLINICAL MODELS AND BEHAVIOURAL INTERPRETATION

Animal models are used to create measurable cognitive impairment and mechanistic stress, but no model fully reproduces human Alzheimer's disease. Scopolamine is useful for cholinergic impairment, aluminium chloride and D-galactose are used for oxidative or ageing-related injury contexts, and amyloid-based models represent selected proteinopathy components. Interpretation should therefore remain model-specific and cautious [81-94].

Table 4. Behavioural and biochemical endpoints used in neuroprotection studies.

Endpoint	Primary parameter	Interpretation
Morris water maze	Escape latency and target quadrant time	Spatial learning and memory trend
Y-maze	Spontaneous alternation percentage	Working memory
Elevated plus maze	Transfer latency	Learning and memory index
Passive avoidance	Step-through latency	Retention of aversive memory
AChE assay	Acetylcholinesterase activity	Cholinergic balance
MDA assay	Lipid peroxidation	Oxidative damage
SOD, catalase, GSH	Antioxidant defense	Endogenous protective reserve
Histopathology	Neuronal density and degeneration	Tissue-level support

VI. QUALITY BY DESIGN FOR PRECLINICAL NEUROPROTECTION STUDIES

Quality by Design is useful beyond formulation development because the reliability of a preclinical conclusion depends on controlling critical variables before experimentation begins. In a neuroprotection study, critical sources of variation include compound identity, purity, dose calculation, model induction timing, animal randomization, behavioural testing conditions, assay calibration, histology scoring and statistical method selection.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Table 5. QbD-based risk control in phytoconstituent neuroprotection research.

Risk area	Possible effect	Control strategy
Compound identity and purity	Uncertain dose-response relationship	Certificate of analysis, batch record and storage log
Docking preparation	Incorrect predicted interaction	Standardized protonation, grid and receptor preparation
Dose calculation	Under- or over-dosing	Independent calculation check and dose-volume record
Behavioural testing	Stress or observer bias	Blinding, cleaning and same time-window testing
Biochemical assay	Inconsistent readings	Blank correction, calibration and duplicate/triplicate values
Histology	Subjective interpretation	Coded slides and fixed magnification
Statistics	False-positive or misleading inference	Predefined test and documented outlier handling

VII. TRANSLATIONAL CHALLENGES

The most frequent translational barriers for phytoconstituents include poor aqueous solubility, rapid metabolism, low systemic exposure, limited BBB penetration, batch-to-batch variability and uncertainty in active metabolites. These limitations do not invalidate phytoconstituent research, but they require careful design and restrained interpretation.

Another challenge is the gap between animal models and human Alzheimer's disease. A molecule may improve scopolamine-induced memory impairment without modifying the progressive pathology of human dementia. Therefore, preclinical findings should be described as neuroprotective, antioxidant, cholinergic or model-specific effects rather than direct clinical efficacy.

VIII. FUTURE PERSPECTIVES

Future work should combine verified docking, molecular dynamics, standardized ADMET prediction, improved formulations, dose-response studies, biomarker panels, blinded histopathology and transparent statistical reporting. Multi-compound or formulation-based approaches may be explored, but each component must be chemically characterized and justified. Data repositories, raw-data sheets and reproducibility checklists should become routine in preclinical phytoconstituent research.

IX. CONCLUSION

Phytoconstituents remain valuable candidates for Alzheimer's disease-related neuroprotection research because many possess multi-target chemical and biological features. Their scientific value depends on rigorous screening, ADMET evaluation, ethical pharmacological validation and careful interpretation. A QbD-supported pathway improves reproducibility and helps prevent overstatement, making it suitable for future dissertation and manuscript development.

REFERENCES

1. Alzheimer's Association. 2025 Alzheimer's disease facts and figures. Alzheimers Dement. 2025;21(5):e70235.
2. World Health Organization. Dementia: fact sheet and public health response. Geneva: WHO; 2025.
3. Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050. Lancet Public Health. 2022;7(2):e105-e125.
4. Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

5. Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer's disease. Alzheimers Dement. 2024;20(8):5143-5169.
6. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590.
7. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14(1):32.
8. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-339.
9. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.
10. Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21(4):306-318.
11. Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.
12. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-β pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503.
13. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68-80.
14. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer's disease. Nat Genet. 2022;54(4):412-436.
15. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463-477.
16. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: current progress and future directions. Alzheimers Dement. 2016;12(6):719-732.
17. Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci. 2018;19(10):610-621.
18. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157-172.
19. Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148-160.
20. Bai R, Guo J, Ye XY, Xie Y, Xie T. Oxidative stress: the core pathogenesis and mechanism of Alzheimer's disease. Ageing Res Rev. 2022;77:101619.
21. Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1403-1416.
22. Reddy PH, Oliver DM. Amyloid beta and phosphorylated tau-induced defective autophagy and mitophagy in Alzheimer's disease. Cells. 2019;8(5):488.
23. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5-21.
24. Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer's disease. Nat Neurosci. 2020;23(10):1183-1193.
25. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541-5554.
26. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
27. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

28. U.S. Food and Drug Administration. FDA converts novel Alzheimer's disease treatment to traditional approval. Silver Spring: FDA; 2023.
29. U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease: Kisunla (donanemab-azbt). Silver Spring: FDA; 2024.
30. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410.
31. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484-496.
32. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66-77.
33. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781.
34. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963.
35. Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid. Nat Med. 2020;26(5):769-780.
36. Atri A. Current and future treatments in Alzheimer's disease. Semin Neurol. 2019;39(2):227-240.
37. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25(1):59-70.
38. Breijyeh Z, Karaman R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules. 2020;25(24):5789.
39. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology. 2014;76 Pt A:27-50.
40. Birks JS. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
41. Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem. 2012;55(22):10282-10286.
42. Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-β to tau. Nat Rev Neurol. 2013;9(12):677-686.
43. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:728983.
44. Khan H, Marya, Amin S, Kamal MA, Patel S. Flavonoids as acetylcholinesterase inhibitors: current therapeutic standing and future prospects. Biomed Pharmacother. 2018;101:860-870.
45. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MBH. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy. CNS Neurosci Ther. 2008;14(4):352-365.
46. Mishra S, Palanivelu K. The effect of curcumin on Alzheimer's disease: an overview. Ann Indian Acad Neurol. 2008;11(1):13-19.
47. Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia. Pharmacol Biochem Behav. 2009;91(4):554-559.
48. Bastianetto S, Ménard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta. 2015;1851(9):1195-1201.
49. Shen LR, Parnell LD, Ordovas JM, Lai CQ. Curcumin and aging. Biofactors. 2013;39(1):133-140.
50. Zhang C, Browne A, Child D, Tanzi RE. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem. 2010;285(37):28472-28480.